Authors

Latest:

Dr. Chao on Minimal Residual Disease in ALL

Nelson Jen An Chao, MD, professor of medicine, Donald D. and Elizabeth G. Cooke Cancer Research Professor, chief, Division of Cell Therapy in the Department of Medicine, Duke Cancer Institute, discusses minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL).

Nicholas A. Butowski, MD

Latest:

Dr. Butowski on Real-Time Imaging of Nanoliposomal Irinotecan Injection

Nicholas A. Butowski, MD, discusses an early-stage study of convection-enhanced delivery of nanoliposomal irinotecan with real-time imaging.

Nicholas Aksu

Latest:

Where Sipuleucel-T Fits in the Treatment of mCRPC

Sipuleucel-T received an FDA approval in 2010 and a subsequent CMS coverage decision in 2011. At Lancaster Urology in Pennsylvania, we began infusing sipuleucel-T in 2011, and at the 7-year mark, we conducted a review to evaluate these first years of therapy.

Nicholas Butowski, MD

Latest:

Dr. Butowski Discusses Dianhydrogalactitol in Patients with Recurrent GBM

Nicholas Butowski, MD, associate professor, University of California, San Francisco, neuro-oncologist, UCSF Medical Center, discusses a phase I/II study of dianhydrogalacitol in patients with recurrent glioblastoma multiforme (GBM).

Nicholas C. Rohs, MD

Latest:

Dr Rohs on Pityriasis Rubra Pilaris as an Early Signal of Lung Cancer Recurrence

Nicholas C. Rohs, MD, discusses a case study that he presented during the Interesting Cases session at the 18th Annual New York Lung Cancers Symposium®.

Nicholas G. Cost, MD

Latest:

Dr. Cost on Pembrolizumab Plus Axitinib in Patients With RCC

Nicholas G. Cost, MD, assistant professor, Surgery-Urology, Department of Pediatric Urology/ Urologic Oncology, University of Colorado Denver, discusses a clinical trial exploring pembrolizumab (Keytruda) plus axitinib (Inlyta) in patients with renal cell carcinoma (RCC).

Nicholas J. Robert, MD

Latest:

Expanding Opportunities for Real-World Evidence in Oncology

Real-world evidence is finding an expanded role in oncology, prompting experts to rethink how data are gathered on the day-to-day usefulness of drugs for regulatory decisions.

Nicholas J. Vogelzang, MD

Latest:

Updates in Genitourinary, Gynecologic Cancers From ASCO 2021: Drs Nick Vogelzang and Erin Crane

OncLive sits down with Nicholas J. Vogelzang, MD, and Erin K. Crane, MD, MPH to discuss the biggest abstracts in genitourinary cancers and gynecologic cancers, respectively, at the 2021 ASCO Annual Meeting.

Nicholas J. Vogelzang, MD, FASCO, FACP, Comprehensive Cancer Centers of Nevada

Nicholas James, MBBS, PhD University of Birmingham

Nicholas Patrick McAndrew MD, MSCE

Latest:

Dr McAndrew on a Subgroup Analysis of NATALEE in HR+/HER2– Early Breast Cancer

Nicholas P. McAndrew, MD, MSCE, discusses a subgroup analysis of the NATALEE trial in HR+/HER2– early breast cancer by prior systemic treatment.

Nicholas Turner, PhD

Latest:

Dr. Turner Discusses the PALOMA-3 Trial

Nicholas Turner, PhD, discusses the PALOMA-3 trial, which studied palbociclib combined with fulvestrant for the treatment of patients with hormone receptor-positive, HER2-negative metastatic breast cancer after endocrine failure.

Nicholas Vogelzang, MD, Comprehensive Cancer Center

Latest:

The Emerging Role of Chemotherapy in Metastatic Prostate Cancer

Nichole Tucker

Latest:

Smoldering Multiple Myeloma Management Hinges on the Debate Between Treatment and Observation

The smoldering multiple myeloma treatment paradigm harbors fractures in the consensus regarding the optimal management of this disease, with some experts favoring a watch-and-wait approach and others advocating for early treatment.

Nichon L. Grupka, MD

Latest:

Dr. Grupka on Mutations in Patients With Myelodysplastic Syndrome

Nichon L. Grupka, MD, pathologist, Novant Health Thomasville Medical Center, discusses the manifestations of mutations in myelodysplastic syndrome (MDS).

Nick Rose

Latest:

The Virtual Window: Clinical Trial Reports--March 2007

Successful research into new therapies for cancer requires a ready supply of patients willing to participate in clinical trials, and physicians and other health care professionals who will refer their patients to the appropriate studies.

Nick Sambides, Jr

Latest:

Oncology Practices Face the Biggest Change in Coding Since the Computer-ICD-10

Set for full rollout on October 1, the much delayed 10th revision of the International Statistical Classification of Diseases and Related Health Problems is probably the biggest revision to medical coding and billing since computerized medical coding and billing practices began decades ago.

Nickolas Papadopoulos, PhD

Latest:

Results of a Combined Modality Screening Approach in Women Without Cancer History

Nickolas Papadopoulos, PhD, professor of oncology and pathology, Johns Hopkins University School of Medicine, discusses the results of a study which evaluated a combined modality screening approach in women without a history of cancer.

Nicola Normanno, MD

Latest:

Dr. Normanno on Using Circulating Tumor DNA for EGFR Detection

Nicola Normanno, MD, chief of the Cell Biology and Biotherapy Unit, INT-Fondazione Pascale, Naples, Italy, discusses the benefit of plasma genotyping to predict response to EGFR-targeted therapy in patients with non-small cell lung cancer (NSCLC).

Nicolas Girard, MD

Latest:

Dr Girard on Mechanisms of Action for TKIs vs ADCs in HER2-Mutated NSCLC

Nicolas Girard, MD, discusses differences in the mechanisms of action for HER2-directed TKIs vs antibody-drug conjugates in HER2-mutant NSCLC.